TARPEYO & lt;sup & gt;TM & lt;/sup & gt; (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults... (Source: McKesson News)
Source: McKesson News - December 22, 2021 Category: Information Technology Source Type: news
TARPEYOTM (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults ... (Source: McKesson News)
Source: McKesson News - December 21, 2021 Category: Information Technology Source Type: news
TARPEYO < sup > TM < /sup > (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults ... (Source: McKesson News)
Source: McKesson News - December 21, 2021 Category: Information Technology Source Type: news
Oral Steroid Gets FDA Approval for IgA Nephropathy Oral Steroid Gets FDA Approval for IgA Nephropathy
Oral budesonide delayed-release (Tarpeyo) became the first agent to receive FDA approval for reducing proteinuria in patients with primary IgA nephropathy and at risk for rapid progression.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 17, 2021 Category: Drugs & Pharmacology Tags: Nephrology News Alert Source Type: news
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
STOCKHOLM, Dec. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ( " Calliditas " ) today announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 15, 2021 Category: Drugs & Pharmacology Source Type: news
FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
What Are the Advantages and Disadvantages of Different Renal Replacement Therapies?
Discussion
Kidneys are amazing in that they filter the blood, eliminate toxins, balance fluids and electrolytes plus have a lot of reserve to do the job they need to do even when injured. Therefore, depending on the problem, chronic renal disease (CRD) often allows time before renal replacement therapy (RRT) is needed. RRT currently is dialysis (peritoneal or hemodialysis) or renal transplant. In general, the patient’s own kidneys do the best job for them but there is always a balance between the problems of CRD and its management, versus the potentially improved renal function with RRT. RRT itself though has a diffe...
Source: PediatricEducation.org - September 13, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Mechanical activation of TRPV4 channels controls albumin reabsorption by proximal tubule cells
In this study, we showed that the ion channel TRPV4 modulated the endocytosis of albumin and low–molecular weight proteins in the proximal tubule. TRPV4 was found at the basolateral side of proximal tubule cells, and its mechanical activation by cell stretching induced Ca2+ entry into the cytosol, which promoted endocytosis. Trpv4–/– mice presented with mild proximal tubule dysfunction under basal conditions. To challenge endocytic function, the permeability of the glomerular filter was altered by systemic delivery of angiotensin II. The proteinuria induced by this treatment was more severe in Trpv4&ndash...
Source: Signal Transduction Knowledge Environment - October 13, 2020 Category: Science Authors: Gualdani, R., Seghers, F., Yerna, X., Schakman, O., Tajeddine, N., Achouri, Y., Tissir, F., Devuyst, O., Gailly, P. Tags: STKE Research Articles Source Type: news
Targeted Drug First to Show Real Promise in IgA Nephropathy Targeted Drug First to Show Real Promise in IgA Nephropathy
The investigational drug reduces serum immunoglobulin levels in patients with IgA nephropathy and persistent proteinuria, interim results from a small study show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2020 Category: Consumer Health News Tags: Nephrology News Source Type: news
Acute kidney injury and end stage kidney disease in severe COVID-19
(ERA-EDTA) Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease. Furthermore, acute kidney injury is a relevant clinical complication in patients with Covid-19 and is associated with a poor prognosis. An autopsy study from Hamburg shows that the novel coronavirus also affects the kidneys. Renal parameters may have prognostic relevance for the course of COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2020 Category: International Medicine & Public Health Source Type: news
Hantavirus Infection With Renal Failure and Proteinuria Hantavirus Infection With Renal Failure and Proteinuria
This report describes a case of hantavirus-associated acute renal failure and proteinuria. How was this case ultimately diagnosed?Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 17, 2020 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news
Proteinuria After Inpatient Acute Kidney Injury Tied to Later Risk
TUESDAY, Jan. 28, 2020 -- Urine albumin-to-creatinine ratio (ACR) measured after acute kidney injury (AKI) predicts subsequent loss of renal function, according to a study published online Jan. 27 in JAMA Internal Medicine.
Chi-yuan Hsu, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 28, 2020 Category: Pharmaceuticals Source Type: news
Rituximab Noninferior to Cyclosporine in Membranous Nephropathy
WEDNESDAY, July 17, 2019 -- In patients with membranous nephropathy at high risk for progressive disease, rituximab is noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and is superior in maintaining... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2019 Category: Pharmaceuticals Source Type: news
MENTOR: Rituximab Is a Winner in Membranous Nephropathy MENTOR: Rituximab Is a Winner in Membranous Nephropathy
The anti-CD20 antibody is clearly superior to cyclosporine in inducing, maintaining proteinuria remission in patients with membranous nephropathy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news
Linagliptin improved albuminuria but effect on eGFR and CV risk in patients with diabetes
(ERA-EDTA) In the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin. The antidiabetes drug reduced albuminuria and HbA1c in all patients, but did not affect the cardiovascular (CV) risk over 2.2 years. Additionally, it had no impact on the glomerular filtration rate (eGFR), a marker of kidney function. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2019 Category: International Medicine & Public Health Source Type: news
